Objective To analyze the risk factors for meconium-stained amniotic fluid(MSAF)in preterm infants and the clinical outcome and prognosis of preterm infants.Methods Preterm infants with gestational age＜37 weeks delivered in Zhangjiajie People's Hospital from January 2022 to December 2023 were used as the study subjects,31 cases with MSAF were in MSAF group,and 31 cases of preterm infants hospitalized during the same period without MSAF were randomly paired in the ratio of 1∶1 to select with gestational age-body mass matching as non-MSAF group.Retrospective collection and analysis of pregnancy and perinatal conditions of mothers of preterm infants in two groups,comparing the differences of related factors between two groups of children;Logistic regression analysis of risk factors related to MSAF in preterm infants;comparing the complications and clinical outcomes of preterm infants in two groups.Results A total of 387 preterm infants with gestational age＜37 weeks were collected during the study period,including 31 preterm infants with comorbid MSAF,and the prevalence of MSAF in preterm infants was 8.0％.MSAF group had a higher incidence of advanced maternal age,premature rupture of membranes＞18 hours,antepartum fever,and cholestasis during pregnancy than non-MSAF group.Logistic regression analysis suggested that combined cholestasis during pregnancy and white blood cell count ≥ 30× 109/L within 6 hours after birth increased the incidence of MSAF in preterm infants.There was no statistically significant difference in the results of postnatal umbilical artery blood gas analysis between two groups of preterm infants.The proportion of leukocyte count ≥30×109/L,ultrasensitive C-reactive protein＞0.8 mg/L,and interleukin 6＞6 pg/L in MSAF group was higher than that of non-MSAF group in the 6 hours after birth.MSAF group had a higher incidence of intrauterine infectious pneumonia,feeding intolerance,and necrotizing small bowel colitis in neonates than non-MSAF group.Conclusion Advanced maternal age,intrauterine infections,and combined intrahepatic cholestasis during pregnancy may be the major risk factors for MSAF in preterm infants.MSAF preterm infants have a higher prevalence of intrauterine infectious pneumonitis,feeding intolerance,and necrotizing small bowel colitis in newborns,as well as longer hospital stays.

Objective To analyze the risk factors for meconium-stained amniotic fluid(MSAF)in preterm infants and the clinical outcome and prognosis of preterm infants.Methods Preterm infants with gestational age＜37 weeks delivered in Zhangjiajie People's Hospital from January 2022 to December 2023 were used as the study subjects,31 cases with MSAF were in MSAF group,and 31 cases of preterm infants hospitalized during the same period without MSAF were randomly paired in the ratio of 1∶1 to select with gestational age-body mass matching as non-MSAF group.Retrospective collection and analysis of pregnancy and perinatal conditions of mothers of preterm infants in two groups,comparing the differences of related factors between two groups of children;Logistic regression analysis of risk factors related to MSAF in preterm infants;comparing the complications and clinical outcomes of preterm infants in two groups.Results A total of 387 preterm infants with gestational age＜37 weeks were collected during the study period,including 31 preterm infants with comorbid MSAF,and the prevalence of MSAF in preterm infants was 8.0％.MSAF group had a higher incidence of advanced maternal age,premature rupture of membranes＞18 hours,antepartum fever,and cholestasis during pregnancy than non-MSAF group.Logistic regression analysis suggested that combined cholestasis during pregnancy and white blood cell count ≥ 30× 109/L within 6 hours after birth increased the incidence of MSAF in preterm infants.There was no statistically significant difference in the results of postnatal umbilical artery blood gas analysis between two groups of preterm infants.The proportion of leukocyte count ≥30×109/L,ultrasensitive C-reactive protein＞0.8 mg/L,and interleukin 6＞6 pg/L in MSAF group was higher than that of non-MSAF group in the 6 hours after birth.MSAF group had a higher incidence of intrauterine infectious pneumonia,feeding intolerance,and necrotizing small bowel colitis in neonates than non-MSAF group.Conclusion Advanced maternal age,intrauterine infections,and combined intrahepatic cholestasis during pregnancy may be the major risk factors for MSAF in preterm infants.MSAF preterm infants have a higher prevalence of intrauterine infectious pneumonitis,feeding intolerance,and necrotizing small bowel colitis in newborns,as well as longer hospital stays.

Objective:To study the effect of pidotimod combined with montelukast sodium in the treatment of patients with asthma, and its influence on the levels of inflammatory factors and immune function.Methods:From February 2019 to February 2020, 102 patients with bronchial asthma admitted to Zhuji People's Hospital were randomly divided into the observation group and the control group, with 51 cases in each group.The control group was treated with montelukast sodium, and the observation group was given pidotimod combined with montelukast sodium.The clinical effect, lung function index, inflammatory factors, T lymphocyte subsets and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.20%(46/51), which was higher than that of the control group [74.51%(38/51)](χ 2=4.317, P=0.038). After treatment, FEV 1, FVC, PEF in the observation group were (82.89±6.94)%, (3.89±0.45)L, (3.49±0.49)L/s, respectively, which were higher than those in the control group [(77.89±6.79)%, (3.58±0.43)L, (3.21±0.45)L/s] ( t=7.370, 5.753, 4.239, all P<0.05). After treatment, the serum levels of procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP) in the observation group were (1.45±0.49)μg/L, (9.87±2.65)mg/L, (5.79±1.48)mg/L, respectively, which were lower than those in the control group [(1.79±0.55)μg/L, (12.34±2.97)mg/L, (7.23±1.68)mg/L] ( t=4.624, 6.542, 8.090, all P<0.05). After treatment, the CD 3+ , CD 4+ , CD 4+ /CD 8+ in the observation group were (53.43±5.43)%, (46.34±5.31)%, (1.54±0.23), respectively, which were higher than those in the control group [(48.09±5.17)%, (41.89±5.15)%, (1.26±0.22)], while the CD 8+ in the observation group[(30.65±3.54)%] was lower than that in the control group[(33.72±3.69)%], the differences were statistically significant ( t=3.901, 4.080, 4.072, 5.967, all P<0.05). During the treatment period, the incidences of adverse reactions in the observation group and the control group were 15.69%(8/51) and 9.80%(5/51), respectively, there was no statistically significant difference between the two groups (χ 2=0.793, P=0.373). Conclusion:Pidotimod combined with montelukast sodium has significant therapeutic effect on bronchial asthma.It can improve the pulmonary function, reduce the levels of inflammatory factors, improve the immune function of the body, and has good therapeutic safety.It has a high clinical application value.